ORLANDO, Fla., Dec. 9, 2013 /PRNewswire/ -- Cadence Pharmaceuticals, Inc. (NASDAQ: CADX), a biopharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting, announced today that results from a new study analyzing large-scale hospital billing data will be presented today at two major healthcare conferences. The study examined the impact of Cadence's IV acetaminophen therapy, OFIRMEV® (acetaminophen) injection, on certain healthcare-related outcomes in the perioperative setting. The data from this study will be presented in Orlando, Florida, at the American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and at the Institute for Health Improvement (IHI) National Forum.
The study evaluated data from more than 22,000 inpatient admissions for major joint repair procedures from a hospital research database of more than 550 hospitals maintained by the Premier healthcare alliance. In the analysis, 11,073 patients who underwent elective major joint arthroplasty and who received OFIRMEV on the day of surgery were matched to 11,073 patients who did not receive the treatment during their stay. Researchers compared data from the two groups to assess differences in certain patient outcomes, including hospital length-of-stay, and average hospital costs.
"This research is very encouraging and demonstrates how integrating IV acetaminophen as a foundation for multimodal surgical analgesia may positively impact the cost of care and outcomes for surgical patients," said Ted Schroeder, President and CEO of Cadence. "Multiple medical societies have endorsed multimodal analgesia to optimize pain outcomes while reducing opioid use in order to minimize side effects often seen with narcotics. We look forward to working with medical professionals to help implement multimodal treatment strategies."
About the data
Evaluation of Patient Outcomes, Length of Stay, and Average Hospital Costs with IV Acetaminophen: A Case-Matched Analysis of a National Inpatient Hospital Database. Christian Apfel, M.D., Ph.D., Adjunct Associate Professor, Department of Epidemiology and Biostatistics, UCSF, San Francisco, CA. (ASHP abstract 3-127)
Effect of IV acetaminophen on Postoperative Outcomes, Length of Stay and Costs: National Hospital Database Analysis of 11,073 Matched Pairs. Presenter: Gary Oderda, Pharm.D., M.P.H., Professor, Director, Pharmaceutical Outcomes Research Center, University of Utah College of Pharmacy, Salt Lake City, UT. (IHI poster 32)
About OFIRMEV® (Acetaminophen) Injection
OFIRMEV (acetaminophen) injection (1000 mg / 100 mL, 10 mg / mL; for intravenous use only), Cadence Pharmaceuticals' proprietary intravenous formulation of acetaminophen, is indicated for the management of mild to moderate pain, the management of moderate to severe pain with adjunctive opioid analgesics, and the reduction of fever. The effectiveness of OFIRMEV for the treatment of acute pain and fever has not been studied in pediatric patients less than 2 years of age.
Important Safety Information
RISK OF MEDICATION ERRORS AND HEPATOTOXICITY
Take care when prescribing, preparing, and administering OFIRMEV injection to avoid dosing errors which could result in accidental overdose and death.
OFIRMEV contains acetaminophen. Acetaminophen has been associated with cases of acute liver failure, at times resulting in liver transplant and death. Most of the cases of liver injury are associated with the use of acetaminophen at doses that exceed the recommended maximum daily limits, and often involve more than one acetaminophen-containing product.
OFIRMEV is contraindicated in patients with severe hepatic impairment, severe active liver disease or with known hypersensitivity to acetaminophen or to any of the excipients in the formulation. Acetaminophen should be used with caution in patients with the following conditions: hepatic impairment or active hepatic disease, alcoholism, chronic malnutrition, severe hypovolemia, or severe renal impairment. Rarely, acetaminophen may cause serious skin reactions such as acute generalized exanthematous pustulosis (AGEP), Stevens-Johnson Syndrome (SJS), and toxic epidermal necrolysis (TEN), which can be fatal. Discontinue OFIRMEV immediately if symptoms associated with allergy or hypersensitivity occur, or at the first appearance of skin rash. Do not use in patients with acetaminophen allergy.
The most common adverse reactions in patients treated with OFIRMEV were nausea, vomiting, headache, and insomnia in adult patients and nausea, vomiting, constipation, pruritus, agitation, and atelectasis in pediatric patients. The antipyretic effects of OFIRMEV may mask fever in patients treated with postsurgical pain. Do not exceed the recommended maximum daily dose of OFIRMEV. OFIRMEV should be administered only as a 15-minute infusion.
About Cadence Pharmaceuticals, Inc.
Cadence Pharmaceuticals is a pharmaceutical company focused on acquiring, in-licensing, developing and commercializing proprietary products principally for use in the hospital setting. OFIRMEV® was approved by the FDA in November 2010, launched in early 2011, and is now used in over 4,600 hospitals nationwide with an estimated 5.5-6.9 million hospitalized patients treated through October 31, 2013, based on an estimate of 2-2.5 doses per patient. The current version of Cadence Pharmaceuticals' corporate overview may be viewed on the Investors page of www.cadencepharm.com under "Events & Presentations" by selecting "Corporate Overview."
William R. LaRue
SVP & Chief Financial Officer
Cadence Pharmaceuticals, Inc.
Phone: (858) 436-1400
Marites Cristobal Coulter
Phone: (323) 202-1424
Cell: (415) 819-2214
SOURCE Cadence Pharmaceuticals, Inc.